Education
About Us
Working with TipRanks
Follow Us
Amarin Corporation Plc (AMRN)
NASDAQ:AMRN
Top Page
Amarin
(NASDAQ:AMRN)
Select Model
Select Model
Rating:50Neutral
Price Target:
$17.00
▼(-16.05% Downside)
Amarin's overall stock score reflects a challenging financial position with ongoing losses and cash flow issues. The positive momentum in the U.S. market and strategic cost reductions are encouraging, but valuation concerns and mixed technical indicators weigh on the score. The earnings call provided a more optimistic outlook, but significant risks remain.
Amarin (AMRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$284.94M
Dividend YieldN/A
Average Volume (3M)91.78K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue Growth-6.31%
EPS Growth-115.62%
CountryUS
Employees275
SectorN/A
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding20,792,685
10 Day Avg. Volume103,188
30 Day Avg. Volume91,775
Financial Highlights & Ratios
PEG Ratio-1.46
Price to Book (P/B)8.20
Price to Sales (P/S)17.44
P/FCF Ratio-128.50
Enterprise Value/Market Cap0.16
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit0.50
Enterprise Value/Ebitda-0.85
Forecast
1Y Price Target
$10.00Price Target Upside-50.62% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Amarin Business Overview & Revenue Model
Company DescriptionAmarin Corporation plc is a biopharmaceutical company focused on developing and commercializing innovative therapeutics to improve cardiovascular health. The company is primarily known for its flagship product, Vascepa (icosapent ethyl), an omega-3 fatty acid approved for use in reducing cardiovascular risk in patients with high triglyceride levels. Amarin operates within the pharmaceutical sector, specifically in the cardiovascular disease treatment market, and is committed to advancing scientific research and development to address unmet medical needs.
How the Company Makes MoneyAmarin generates revenue primarily through the sale of its flagship product, Vascepa, which is marketed to healthcare providers and patients for the treatment of cardiovascular conditions. The company earns income from prescription sales in various markets, including the United States, where it has established a robust distribution network. Additionally, Amarin may enter into partnerships or collaborations with other pharmaceutical companies to develop or commercialize new products, which can provide additional revenue streams. The company also benefits from patent protections and exclusivity periods for its products, allowing it to capture a significant share of the market before facing generic competition. Overall, its revenue model relies heavily on the successful promotion and sale of its approved therapeutics, alongside potential future product developments and collaborations.
Amarin Earnings Call Summary
Earnings Call Date:Oct 29, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 03, 2026
Earnings Call Sentiment Positive
The earnings call reflected a positive outlook due to significant growth in U.S. market sales, successful partnerships, and strategic cost reductions. However, challenges remain with declining Rest of World revenue and ongoing restructuring costs.Q3-2025 Updates
Positive Updates
Increase in Total Net Revenue
Total net revenue for Q3 2025 was $49.7 million, an increase of $7.4 million or 17% compared to the prior year period, primarily reflecting higher U.S. sales.
U.S. Market Performance
Net product revenue in the U.S. was $40.9 million, an increase of $10.3 million or 34%, driven by an increase in net selling price and volume.
Successful Partnership with Recordati
The transition to a fully partnered commercial model in Europe is progressing well, with sustained momentum and growth in demand across all commercialized European markets.
Cost Savings and Restructuring
SG&A expenses were reduced by $17.2 million or 47% over the prior year period, indicating the benefits of organizational restructuring.
FDA Labeling Update on Fenofibrates
The FDA revised the labeling of fenofibrates to include a statement on the lack of cardiovascular benefit, which may shift clinical practice towards proven therapies like VASCEPA.
Negative Updates
Decline in Rest of World Revenue
Product revenue for the Rest of World business was $3.6 million, a decline from the prior year, indicating variability and challenges in these markets.
European Revenue Consistency
European product revenue remained consistent with the prior year at $4.1 million, but did not show the same growth as the U.S. market.
Ongoing Restructuring Costs
Restructuring expenses were $9.4 million, contributing to an operating loss of $11.1 million, although these costs are expected to decrease moving forward.
Company Guidance
During Amarin Corporation's third-quarter 2025 earnings call, the company reported a total net revenue of $49.7 million, marking a 17% increase compared to the previous year. This growth was primarily driven by the U.S. net product revenue, which reached $40.9 million, a 34% increase due to changes in customer mix and regained exclusivity with a large pharmacy benefit manager. The company has successfully transitioned to a fully partnered commercial model outside the U.S., with the European operations handed over to Recordati, generating $4.1 million in product revenue. The company also reported significant operational cost savings, reducing SG&A expenses by 47% year-over-year, and anticipates achieving positive free cash flow by 2026. Despite a decline in rest-of-world revenue, the company remains focused on leveraging its partnerships to expand VASCEPA's market reach globally, with a strategic emphasis on cardiovascular risk reduction. The FDA's recent labeling update on fenofibrates is expected to further highlight VASCEPA's benefits.Amarin Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
50
Neutral
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Amarin Technical Analysis
Neutral
20.25
Price Trends
16.16
Negative
16.12
Negative
14.10
Positive
Market Momentum
-0.68
Negative
40.14
Neutral
35.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRN, the sentiment is Neutral. The current price of 20.25 is above the 20-day moving average (MA) of 14.65, above the 50-day MA of 16.16, and above the 200-day MA of 14.10, indicating a neutral trend. The MACD of -0.68 indicates Negative momentum. The RSI at 40.14 is Neutral, neither overbought nor oversold. The STOCH value of 35.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMRN.
Amarin Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
78 Outperform | $810.28M | 7.14 | 220.06% | ― | 79.13% | 2798.12% | |
50 Neutral | $284.94M | -3.39 | -17.35% | ― | -6.31% | -115.62% | |
46 Neutral | $415.28M | ― | -52.61% | ― | -61.54% | 31.25% | |
41 Neutral | $558.62M | -14.40 | -35.82% | ― | ― | 79.27% | |
40 Underperform | $379.86M | -1.55 | -74.88% | ― | ― | 18.39% | |
37 Underperform | $317.66M | -7.36 | -64.31% | ― | ― | 4.23% |
* Sector Average
AMRN
Amarin
14.14
5.18
57.81%
ALT
Altimmune
3.86
-3.81
-49.67%
RIGL
Rigel
44.01
27.51
166.73%
ALDX
Aldeyra Therapeutics
5.31
0.37
7.49%
RCKT
Rocket Pharmaceuticals
3.48
-8.27
-70.38%
CRVS
Corvus Pharmaceuticals
7.70
2.49
47.79%
Amarin Corporate Events
Executive/Board Changes
Amarin Appoints David Keenan as COO
Neutral
Oct 22, 2025
David Keenan, Ph.D., has been appointed as the Executive Vice President and Chief Operating Officer of Amarin Corporation, effective October 17, 2025. Dr. Keenan, who joined Amarin in May 2022, brings over 30 years of leadership experience in the biopharmaceutical and medical device industries, with expertise in operations, quality management, and international M&A.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.